The founding CEO of Moderna Therapeutics, Stéphane Bancel, has joined the board of Syros Pharmaceuticals.
Syros, which focuses on controlling a person’s genes to treat cancer and other diseases, will benefit from Bancel’s work in RNA therapeutics at Moderna.
The company’s CEO Nancy Simonian said: “Stéphane has established an exceptional track record of accomplishment in our industry. His successes in financing and building companies as well as in creating value are widely admired.”
Bancel joined Moderna in 2011, the year after its formation. Notable achievements as CEO include securing a licensing partnership with AstraZeneca potentially worth more than $400m.
Prior to serving as Moderna’s CEO, Bancel spent four years as CEO of bioMérieux.
He also spent six years at Lilly, including a spell as country manager for Belgium.
Commenting on his appointment to the board of Syros, he said: “Syros’ leadership in understanding gene control opens entirely new avenues to treat cancer and other serious diseases.
“The company’s revolutionary approach creates significant opportunity to impact health and create value.”